All around the world, gout prevalence is growing at an alarming pace, while gout treatment remains as “horribly mismanaged” as ever.
This rapid growth has spurred on a worldwide “gout epidemic,” James O’Dell, MD, Robert L. Grissom professor of internal medicine and vice chair and chief of rheumatology at the University of Nebraska Medical Center, in Omaha, who, told the attendees at the American College of Rheumatology Covergence 2021 annual meeting.
Continue reading “‘Horribly mismanaged’: Debate over gout treatment rages as cases surge”
May 31, 2022, 12:30 PM HST Maui News
An analysis of nearly two decades of data of 92,000 people revealed Native Hawaiians had more than twice the risk of Whites participants of developing gout as older adults.
The new study by University of Mānoa researchers — and one of the largest multiethnic gout studies to date — was published in The Journal of Rheumatology.
Gout, a common and painful form of arthritis, is becoming more prevalent in the United States. But the differences in risk between populations remains largely understudied, especially for Native Hawaiians. This study helped shed some light on these differences. It also revealed black participants had the second highest risk, followed by Japanese participants.
Continue reading “Native Hawaiians have higher risk for gout, UH study finds”
The ABCG2 gene belongs to a group of genes called the ATP-binding cassette family; genes in this family provide instructions for making proteins that transport molecules across cell membranes. In the intestines, the ABCG2 protein helps release (secrete) a substance called urate into the urine. Urate is a byproduct of certain normal biochemical reactions in the body. In the bloodstream it acts as an antioxidant, protecting cells from the damaging effects of unstable molecules called free radicals. Urate levels are regulated by the kidneys and, to a lesser extent, by the intestines.
The ABCG2 protein also transports certain drugs out of cells. For example, this protein clears some chemotherapy drugs from organs and tissues. Transport of these drugs allows them to have their intended effects and be eliminated from the body.
Continue reading “Gout: The Other Gene That Affects Urate Levels and Gout Development”
The SLC2A9 gene provides instructions for making a protein called glucose transporter 9 (GLUT9). This protein is found mainly in the kidneys, specifically in structures called proximal tubules. These structures help to reabsorb needed nutrients, water, and other materials into the blood and excrete unneeded substances into the urine. Within the proximal tubules, the GLUT9 protein helps reabsorb or excrete a substance called urate. Urate is a byproduct of certain normal biochemical reactions in the body. In the bloodstream it acts as an antioxidant, protecting cells from the damaging effects of unstable molecules called free radicals. When more urate is needed in the body, the GLUT9 protein helps reabsorb it into the bloodstream. Most urate that is filtered through the kidneys is reabsorbed into the bloodstream; about 10 percent is released into urine.
The GLUT9 protein also plays a role in reabsorbing and excreting the simple sugar glucose.
Continue reading “Gout: Genes that Affect Urate Levels and Gout Development”
Genetic and genetic mutations can certainly play a role in disease, however, poor nutrition and a sedentary lifestyle can greatly increase the risk. Gout is a common condition, but it occurs more frequently in some populations than others. For example, gout occurs in 1 percent of people with Asian ancestry, 3 to 4 percent of people with European ancestry, and 6 to 8 percent of Indigenous (native) Taiwanese peoples and Māori from New Zealand.
Continue reading “Gout: Genetics or Lifestyle Driven?”
In about 15 percent of people with gout, urate accumulates in the kidneys
and forms kidney stones . As the condition worsens, urate crystals can also be deposited under the skin or in other soft tissue, forming a nodule called a tophus (plural: tophi). These tophi often form in the hands, elbows, or feet. Tophi do not typically cause pain, but they can become inflamed, infected, or ooze fluid. Depending on their location, tophi can interfere with movements such as walking or gripping objects.
As we know, many studies have linked Gout with chronic inflammation and obesity. Both conditions contribute a group of factors that increase the risks of heart disease, stroke, and diabetes – also known as metabolic syndrome. Metabolic syndrome is a cluster of biochemical and physiological abnormalities affecting an estimated 50 million Americans.
Continue reading “Gout and Metabolic Disease: Can Probiotics help?”
1) Try to get an accurate diagnosis if possible.
HOWEVER, these suggestions are accurate and helpful with any inflammatory attack and can be followed, regardless of a firm diagnosis. Blood testing can be very misleading. Arthrocentesis, or joint aspiration, is the only secure method of evaluating any crystallized deposits in the joints.
2) Take the right anti-inflammatory medications. Continue reading “What can you do to alleviate Gout symptoms?”
This is somewhat of a loaded question, overall. If we are speaking of an actual Gout “attack”, then yes, for the most part, it will go away. Most Gout attacks will eventually subside, with or without treatment. The attacks will generally reach its peak 12-24hrs after onset and then slowly begin to resolve, usually with full recovery in one to two weeks. Some Gout sufferers only experience 1-2 attacks per year, and those that are lucky, only 1-2 times in their lifetime. However, Chronic Gout sufferers can experience frequent attacks with very little time in between — with some so unfortunate as to never have a full resolution of inflammation and pain in between attacks. This stage of chronic Gout can cause a great deal of joint destruction and even deformity once tophi (hard uric acid deposits under the skin) has formed. Continue reading “Does Gout Go Away?”
Cardiovascular Disease and Gout
The prevalence of cardiovascular disease continues to rise and is among the leading cause of mortality in the world. Inflammatory conditions such as Rheumatoid Arthritis and Gout are often associated with a higher risk and earlier onset of this disease. Research links gout to an increased risk of several types of cardiovascular disease, including heart attack, heart failure, and atrial fibrillation, or an irregular heartbeat. Epidemiological, experimental, and clinical data show that patients with hyperuricemia SUA are at increased risk of cardiac, renal, and vascular damage and CV events. Continue reading “Does Gout Increase The Cardiovascular Disease Risk Factor?”
Uloric (Febuxostat) was FDA approved in 2009 as a means to treat Gout, a form of arthritis. The FDA has since concluded that there is an increased risk of heart-related death and death from all causes from Uloric and now requiring a boxed label warning.
The makers of Uloric (Febuxostat) are also recommending that health care professionals reserve prescribing it only to patients that have failed to achieve relief from Allopurinol or those that were unable to tolerate Allopurinol.
The makers of Uloric, Takeda Pharmaceuticals, were forced to include a “precaution” about possible cardiovascular events in patients at the time of release but has since been updated to the most prominent warning, a boxed warning. Sadly, Takeda Pharmaceuticals was able to manufacture and sell Uloric in the US without any complication warning on the drug’s label for years.
A safety trial was conducted to compare the risks posed by both Allopurinol and Uloric. 15 deaths from heart-related causes per 1,000 patients taking Uloric was observed over a year’s time compared to 11 deaths from heart-related causes per 1,000 treated with Allopurinol. Additionally, 26 deaths from any cause, per 1,000 patients, was observed with Uloric use over that year compared to 22 deaths per 1,000 from Allopurinol. This trial, known as the CARE trial, suggested that Uloric was connected to significantly higher risk for fatal cardiovascular events like heart attacks, strokes, and unstable anginas.
The FDA has been fully aware of these potential complications as early as 2009 and even attempted to minimize the heart problems that Uloric could cause by only approving 40mg and 80mg doses as opposed to the 80mg and 120mg doses that Takeda Pharmaceuticals had requested. Sadly, it took until 2018 for the FDA to require the box label warning based on the results of the postmarket trial that was conducted (CARES).
Uloric (Febuxostat) has also been linked to abnormal liver function. People taking Uloric were shown to have three times higher than normal levels of transaminase. While it remains unlcear as to whether Uloric directly heightens those levels, physicians who prescribe Uloric are supposed to conduct a baseline liver test panel prior to starting Uloric and then continue to monitor for any changes.
Uloric (Febuxostat) has also been linked to severe and potentially fatal allergic reactions. Stevens-Johnson syndrome being one of these observations. Approximately one in 10 people who develop this syndrome fall victim and die from the disease.
The deceptive and faulty marketing that has allowed for years of uninformed use regarding the risk of cardiovascular events has led to numerous lawsuits against Takeda Pharmaceuticals.
Learn More Uloric (Febuxostat)
Learn More About Other Prescription Drugs for Gout
A Careful and Healing Gout Diet